{
    "clinical_study": {
        "@rank": "129631", 
        "arm_group": [
            {
                "arm_group_label": "2.0mg of ALG-1001", 
                "arm_group_type": "Experimental", 
                "description": "2.0mg of ALG-1001"
            }, 
            {
                "arm_group_label": "Intravitreal injection in 0.05cc balanced salt solution.", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Balanced Salt Solution"
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluate the safety and efficacy of ophthalmic intravitreal injection of ALG-1001 in human\n      subjects with symptomatic focal vitreomacular adhesion"
        }, 
        "brief_title": "A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion", 
        "condition": "Symptomatic Focal Vitreomacular Adhesion", 
        "condition_browse": {
            "mesh_term": "Tissue Adhesions"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Symptomatic focal vitreomacular adhesion\n\n          2. Vitreomacular traction syndrome\n\n          3. Stage 1 and 2 macular holes, \u2264 350 \u00b5m\n\n          4. BCVA of 20/25 Early Treatment Diabetic Retinopathy Study (ETDRS) or     worse in the\n             study eye\n\n          5. BCVA of 20/800 ETDRS or better in the fellow eye\n\n          6. Male or female subjects, 18 years of age or older\n\n          7. Signed Informed Consent\n\n        Exclusion Criteria:\n\n          1. High myopes > -8.0 D spherical equivalent\n\n          2. History of prior vitrectomy in the study eye\n\n          3. History of photocoagulation to the retina in the study eye\n\n          4. Macular hole in the study eye > 350 \u00b5m\n\n          5. Subjects with epiretinal membranes in the study eye\n\n          6. Subjects with broad VMA, defined as VMA of >1500 \u00b5m\n\n          7. Subjects with proliferative Diabetic Retinopathy (DR), neovascular Age-related\n             Macular Degeneration (AMD), or retinal vascular occlusion in the study eye\n\n          8. Subjects with aphakia in the study eye\n\n          9. Subjects with uncontrolled glaucoma\n\n         10. Subjects with lenticular or zonular instability\n\n         11. Subjects with prior ocular surgery or intravitreal injection in the study eye within\n             90 days of study enrollment\n\n         12. Pregnant or nursing women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02153476", 
            "org_study_id": "VMA-202"
        }, 
        "intervention": [
            {
                "arm_group_label": "2.0mg of ALG-1001", 
                "intervention_name": "2.0mg of ALG-1001", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Intravitreal injection in 0.05cc balanced salt solution.", 
                "intervention_name": "Balanced Salt Solution", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Boyer, MD", 
                    "phone": "310-289-2478", 
                    "phone_ext": "1243"
                }, 
                "facility": {
                    "address": {
                        "city": "Beverly Hills", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90211"
                    }, 
                    "name": "Retina-Vitreous Associates Medical Group"
                }, 
                "investigator": {
                    "last_name": "David Boyer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Avery, MD", 
                    "phone": "805-963-1648"
                }, 
                "facility": {
                    "address": {
                        "city": "Santa Barbara", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93103"
                    }, 
                    "name": "California Retina Consultants"
                }, 
                "investigator": {
                    "last_name": "Robert Avery, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Tolentino, MD", 
                    "phone": "863-297-5400"
                }, 
                "facility": {
                    "address": {
                        "city": "Winter Haven", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33880"
                    }, 
                    "name": "Center for Retinal and Macular Disease"
                }, 
                "investigator": {
                    "last_name": "Mike Tolentino, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Wong, MD", 
                    "phone": "512-451-0103"
                }, 
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78705"
                    }, 
                    "name": "Austin Retina Associates"
                }, 
                "investigator": {
                    "last_name": "Robert Wong, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Brown, MD", 
                    "phone": "713-524-3434"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Retina Consultants Houston"
                }, 
                "investigator": {
                    "last_name": "David Brown, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint of this study is observation of pharmacologic resolution of VMA, with VMA defined as vitreous adhesion to the macula within a 6mm central retinal field surrounded by elevation of the posterior vitreous cortex as seen on OCT.", 
            "measure": "Release of Vitreo Macular Adhesion (VMA)  by Optical Coherence Tomography (OCT)", 
            "safety_issue": "No", 
            "time_frame": "90 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02153476"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The secondary endpoints of this study are the observations of: (a) non-surgical closure of full thickness macular holes; (b) BCVA; and (c) need for pars plana vitrectomy.", 
            "measure": "1) Non-surgical closure of full thickness macular holes 2) Best Corrected Visual Acuity (BCVA) 3) Need for pars plana vitrectomy (PPV)", 
            "safety_issue": "Yes", 
            "time_frame": "90 days"
        }, 
        "source": "Allegro Ophthalmics, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allegro Ophthalmics, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}